Betta to commercialise C4 Therapeutics’ CFT8919 in greater China
Pharmaceutical Technology
MAY 31, 2023
CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC). C4T can also earn up to $357m in milestone payments and receive low to mid-double-digit percentage royalties on net sales of the product in greater China.
130 
Let's personalize your content